Two Sigma Investments LP bought a new position in shares of Insys Therapeutics Inc (NASDAQ:INSY) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 44,700 shares of the specialty pharmaceutical company’s stock, valued at approximately $156,000.
Other hedge funds have also bought and sold shares of the company. Wells Fargo & Company MN lifted its holdings in shares of Insys Therapeutics by 35.3% during the third quarter. Wells Fargo & Company MN now owns 77,101 shares of the specialty pharmaceutical company’s stock valued at $778,000 after acquiring an additional 20,100 shares during the period. BlackRock Inc. lifted its holdings in shares of Insys Therapeutics by 2.8% during the third quarter. BlackRock Inc. now owns 2,710,787 shares of the specialty pharmaceutical company’s stock valued at $27,325,000 after acquiring an additional 73,282 shares during the period. Jane Street Group LLC bought a new position in shares of Insys Therapeutics during the third quarter valued at $113,000. BlueMountain Capital Management LLC lifted its holdings in shares of Insys Therapeutics by 533.6% during the third quarter. BlueMountain Capital Management LLC now owns 28,145 shares of the specialty pharmaceutical company’s stock valued at $284,000 after acquiring an additional 23,703 shares during the period. Finally, MetLife Investment Advisors LLC bought a new position in shares of Insys Therapeutics during the third quarter valued at $223,000. 16.36% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts have issued reports on INSY shares. Janney Montgomery Scott reissued a “buy” rating and set a $11.00 price objective on shares of Insys Therapeutics in a report on Wednesday, December 19th. ValuEngine raised Insys Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, March 9th. Zacks Investment Research raised Insys Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, January 4th. Royal Bank of Canada cut their price objective on Insys Therapeutics from $9.00 to $7.00 and set an “outperform” rating for the company in a report on Friday, March 8th. Finally, Cantor Fitzgerald started coverage on Insys Therapeutics in a report on Tuesday, January 22nd. They set an “overweight” rating and a $4.40 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $7.28.
Shares of NASDAQ INSY opened at $4.59 on Wednesday. Insys Therapeutics Inc has a 52-week low of $3.35 and a 52-week high of $11.65. The firm has a market cap of $341.63 million, a price-to-earnings ratio of -3.30 and a beta of 2.51.
Insys Therapeutics (NASDAQ:INSY) last announced its earnings results on Thursday, March 7th. The specialty pharmaceutical company reported ($0.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.08). Insys Therapeutics had a negative net margin of 151.79% and a negative return on equity of 1,430.52%. The business had revenue of $16.36 million during the quarter, compared to analyst estimates of $17.93 million. On average, equities research analysts anticipate that Insys Therapeutics Inc will post -1.55 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Two Sigma Investments LP Buys New Holdings in Insys Therapeutics Inc (INSY)” was originally reported by Enterprise Leader and is the sole property of of Enterprise Leader. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://theenterpriseleader.com/2019/04/17/two-sigma-investments-lp-buys-new-holdings-in-insys-therapeutics-inc-insy.html.
Insys Therapeutics Company Profile
Insys Therapeutics, Inc, a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.
Featured Story: Trading Ex-Dividend Strategy
Want to see what other hedge funds are holding INSY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insys Therapeutics Inc (NASDAQ:INSY).
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.